KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $18.8 million.

  • Royalty Pharma's Other Operating Expenses fell 8851.72% to $18.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$206.8 million, marking a year-over-year decrease of 12823.44%. This contributed to the annual value of -$206.8 million for FY2025, which is 12823.44% down from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Other Operating Expenses is $18.8 million, which was down 8851.72% from $12.9 million recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Other Operating Expenses peaked at $924.7 million during Q4 2022, and registered a low of -$238.0 million during Q2 2021.
  • Moreover, its 5-year median value for Other Operating Expenses was $153.8 million (2021), whereas its average is $154.4 million.
  • Examining YoY changes over the last 5 years, Royalty Pharma's Other Operating Expenses showed a top increase of 61304.83% in 2021 and a maximum decrease of 54901.81% in 2021.
  • Quarter analysis of 5 years shows Royalty Pharma's Other Operating Expenses stood at $272.3 million in 2021, then soared by 239.55% to $924.7 million in 2022, then plummeted by 108.27% to -$76.5 million in 2023, then soared by 314.39% to $164.0 million in 2024, then plummeted by 88.52% to $18.8 million in 2025.
  • Its Other Operating Expenses was $18.8 million in Q4 2025, compared to $12.9 million in Q3 2025 and -$111.4 million in Q2 2025.